keyword
MENU ▼
Read by QxMD icon Read
search

Discontinuation of chemotherapy treatment

keyword
https://www.readbyqxmd.com/read/28781821/usefulness-of-a-pharmacist-outpatient-service-for-s-1-adjuvant-chemotherapy-in-patients-with-gastric-cancer
#1
Michio Kimura, Makiko Go, Mina Iwai, Eiseki Usami, Hitomi Teramachi, Tomoaki Yoshimura
S-1 adjuvant chemotherapy is an outpatient treatment for gastric cancer. To evaluate the role of the pharmacist outpatient service in increasing medication adherence and reducing adverse events associated with S-1, the present study retrospectively analyzed prescription recommendations from pharmacists to physicians and the persistence rate of S-1 adjuvant chemotherapy use in patients with gastric cancer. A total of 40 subjects who utilized the pharmacist outpatient service between November 2014 and March 2016 comprised the pharmacist group; and 94 patients who underwent S-1 adjuvant chemotherapy for gastric cancer between September 2012 and October 2014, but not as pharmacist outpatients, comprised the control group...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28781805/successful-oral-desensitization-with-crizotinib-after-crizotinib-induced-hepatitis-in-an-anaplastic-lymphoma-kinase-rearranged-non-small-cell-lung-cancer-patient-a-case-report
#2
Yuto Yasuda, Yasuyo Nishikawa, Yuichi Sakamori, Makoto Terao, Kentaro Hashimoto, Tomoko Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Hiroki Nagai, Hiroaki Ozasa, Toyohiro Hirai, Young Hak Kim
Crizotinib is one of the molecularly-targeted agents targeted against anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). Although its effects appear to be promising, crizotinib may cause adverse effects in patients with ALK-rearranged NSCLC. Hepatic laboratory abnormalities are frequently observed with crizotinib and treatment discontinuation is occasionally required. We herein report the case of a 51-year-old woman diagnosed with relapsed ALK-rearranged NSCLC, who received crizotinib as second-line systemic chemotherapy...
August 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28777427/paclitaxel-oxaliplatin-5-fluorouracil-and-leucovorin-combination-chemotherapy-in-patients-with-recurrent-or-metastatic-gastric-cancer
#3
Yan-Qin Lan, Ri-Ping Wu, Xiao-Bing Huang, Xin-Li Wang, Dong-Ta Zhong, Chuan-Yong Huang, Jin-Tian Song
PURPOSE: This study evaluated the efficacy and toxicity of combination chemotherapy with paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin (POFL) in patients with recurrent or metastatic gastric cancer. METHODS: One hundred and thirty-eight patients with histologically confirmed recurrent or metastatic gastric adenocarcinoma were treated with the POFL regimen: paclitaxel at a dose of 135 mg/m2 as a 3-hour intravenous infusion on day 1, oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 as an intravenous infusion over 2 hours on day 1, followed by 5-fluorouracil 2,400 mg/m2 as an infusion over a 46-hour period on 3 consecutive days, in a 2-week cycle...
July 27, 2017: Tumori
https://www.readbyqxmd.com/read/28772281/randomised-phase-2-study-of-maintenance-linsitinib-osi-906-in-combination-with-erlotinib-compared-with-placebo-plus-erlotinib-after-platinum-based-chemotherapy-in-patients-with-advanced-non-small-cell-lung-cancer
#4
Tudor-Eliade Ciuleanu, Samreen Ahmed, Joo-Hang Kim, Jörg Mezger, Keunchil Park, Michael Thomas, Jihong Chen, Srinivasu Poondru, Jan M VanTornout, Debbie Whitcomb, Fiona Blackhall
BACKGROUND: Maintenance therapy is important in advanced/metastatic non-small cell lung cancer (NSCLC). Erlotinib as switch maintenance following platinum-based chemotherapy increases survival. Cross-talk between the epidermal growth factor receptor and insulin-like growth factor receptor (IGFR) pathways mediate resistance to individual receptor blockade. This study compared maintenance linsitinib plus erlotinib vs erlotinib plus placebo in patients with NSCLC. METHODS: In this Phase II randomised trial, patients without progression following four cycles of first-line platinum-based chemotherapy (N=205) received continuous schedule maintenance oral linsitinib 150 mg or placebo BID combined with erlotinib 150 mg QD for 21-day cycles...
August 3, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28771961/phase-i-study-of-pemetrexed-and-concurrent-radiotherapy-for-previously-untreated-elderly-patients-with-locally-advanced-non-squamous-non-small-cell-lung-cancer
#5
Shinnosuke Takemoto, Yoichi Nakamura, Minoru Fukuda, Hiroaki Senju, Hiroshi Gyotoku, Hirokazu Taniguchi, Midori Shimada, Takaya Ikeda, Hiroyuki Yamaguchi, Katsumi Nakatomi, Nobuyuki Hayashi, Hiroshi Soda, Hiroshi Mukae
BACKGROUND: Chemoradiotherapy is the standard treatment for locally advanced non-small cell lung cancer (NSCLC); however, it is disputed whether this treatment is suitable for patients aged ≥75. This study was conducted to determine the maximum tolerated dose (MTD) of pemetrexed for use in concurrent radiotherapy for elderly patients with locally advanced non-squamous NSCLC. METHODS: The eligibility criteria were as follows: aged ≥75 with inoperable stage IIIA or IIIB non-squamous NSCLC, no history of chemotherapy or radiotherapy, a performance status of 0 or 1, and adequate organ function...
August 3, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28768965/reactivation-of-occult-hepatitis-b-virus-infection-27-months-after-the-end-of-chemotherapy-including-rituximab-for-malignant-lymphoma
#6
Junichi Muraishi, Michihiko Shibata, Yuichi Honma, Masaaki Hiura, Shintaro Abe, Masaru Harada
A 68-year-old man with occult hepatitis B virus (HBV) infection was diagnosed with malignant lymphoma and achieved complete remission after treatment with a chemotherapy regimen including rituximab for 5 months. Entecavir (ETV) was also used during and after chemotherapy and was ended at 14 months after chemotherapy. However, reactivation of HBV was observed in blood tests, which showed not only elevation of HBV-DNA but also HBsAg and HBeAg, at 27 months after the end of chemotherapy. After restarting ETV, the HBV-DNA levels immediately subsided...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28763329/efficacy-of-modified-dose-dense-paclitaxel-in-recurrent-cervical-cancer
#7
Hiroko Machida, Aida Moeini, Marcia A Ciccone, Sayedamin Mostofizadeh, Tsuyoshi Takiuchi, Laurie L Brunette, Lynda D Roman, Koji Matsuo
OBJECTIVE: To examine survival outcomes of women with recurrent cervical cancer who received salvage chemotherapy with modified dose-dense paclitaxel (MDDP) monotherapy (paclitaxel 80 mg/m, administered on day 1, 8, and 15 without day 22). MATERIALS AND METHODS: A retrospective study was conducted to evaluate cause-specific survival after the first recurrence (SAR) of women with recurrent cervical cancer diagnosed between 2006 and 2014. Pooled analyses were performed to examine SAR in women who received MDDP monotherapy (n=17) for any treatment line, compared with those who received salvage chemotherapy with paclitaxel-doublet (n=18) and nonpaclitaxel regimens (n=52)...
July 31, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28758697/renal-toxicity-and-chemotherapy-in-children-with-cancer-nephrotoxicity-and-cancer-treatment
#8
REVIEW
A Ruggiero, P Ferrara, G Attinà, D Rizzo, R Riccardi
Antineoplastic drugs' clinical use can be limited by different drug-induced toxicities. Of these, renal dysfunction may be one of the most troublesome in that it can be cumulative and in general is only partially reversible with the discontinuation of the treatment. Renal toxicity may be manifested as a reduction of the glomerular filtration rate, electrolyte imbalances, or frank renal failure. Careful assessment of renal function has to be performed taking into account that the impairment of the renal function is initially silent and only later may be clinically dramatic...
July 31, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28753851/safety-and-antitumour-activity-of-odm-201-bay-1841788-in-chemotherapy-na%C3%A3-ve-and-cyp17-inhibitor-na%C3%A3-ve-patients-follow-up-from-the-arades-and-arafor-trials
#9
Neal D Shore, Teuvo L Tammela, Christophe Massard, Petri Bono, John Aspegren, Mika Mustonen, Karim Fizazi
BACKGROUND: ODM-201, a new androgen receptor antagonist for treatment of metastatic castration-resistant prostate cancer (mCRPC), demonstrated antitumour activity and acceptable tolerability in phase 1/2 trials. OBJECTIVE: To determine the antitumour activity and safety profile of extended treatment with ODM-201 in men with mCRPC. DESIGN, SETTING, AND PARTICIPANTS: ARADES and ARAFOR trials with ODM-201 enrolled chemotherapy-naïve and CYP17 inhibitor (CYP17i)-naïve mCRPC patients...
February 14, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28748102/kamishoyosan-and-shakuyakukanzoto-promote-recovery-from-paclitaxel-induced-neurite-retraction-in-pc12-cells
#10
Ken Konaka, Kota Moriyama, Takumi Sakurada, Naoto Okada, Masaki Imanishi, Yoshito Zamami, Kazuyoshi Kawazoe, Shuji Fushitani, Keisuke Ishizawa
BACKGROUND: In chemotherapy, the full round of treatment must be completed as scheduled to achieve the strongest therapeutic effect. However, peripheral neuropathy, a severe side effect of the chemotherapeutic agent paclitaxel, can force the premature discontinuation of treatment. As some kampo practitioners have suggested that it may be possible to counteract such side effects, we analyzed the effects of Kamishoyosan, Shakuyakukanzoto, and Goshajinkigan in an in vitro model of paclitaxel-induced peripheral neuropathy...
2017: Journal of Pharmaceutical Health Care and Sciences
https://www.readbyqxmd.com/read/28747442/chemotherapy-induced-peripheral-neuropathy-clinical-trials-review-and-recommendations
#11
REVIEW
Jennifer S Gewandter, Roy Freeman, Rachel A Kitt, Guido Cavaletti, Lynn R Gauthier, Michael P McDermott, Nimish A Mohile, Supriya G Mohlie, A Gordon Smith, Mohamedtaki A Tejani, Dennis C Turk, Robert H Dworkin
OBJECTIVE: To assess the design characteristics and reporting quality of published randomized controlled trials (RCTs) for treatments of chemotherapy-induced peripheral neuropathy (CIPN) initiated before or during chemotherapy. METHODS: In this systematic review of RCTs of preventive or symptomatic pharmacologic treatments for CIPN initiated before or during chemotherapy treatment, articles were identified by updating the PubMed search utilized in the CIPN treatment guidelines published in the Journal of Clinical Oncology in 2014...
July 26, 2017: Neurology
https://www.readbyqxmd.com/read/28741618/the-immune-contexture-in-cancer-prognosis-and-treatment
#12
REVIEW
Wolf H Fridman, Laurence Zitvogel, Catherine Sautès-Fridman, Guido Kroemer
Immunotherapy is currently the most rapidly advancing area of clinical oncology, and provides the unprecedented opportunity to effectively treat, and even cure, several previously untreatable malignancies. A growing awareness exists of the fact that the success of chemotherapy and radiotherapy, in which the patient's disease can be stabilized well beyond discontinuation of treatment (and occasionally is cured), also relies on the induction of a durable anticancer immune response. Indeed, the local immune infiltrate undergoes dynamic changes that accompany a shift from a pre-existing immune response to a therapy-induced immune response...
July 25, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28739752/severe-cardiotoxicity-in-a-patient-with-colorectal-cancer-treated-with-bevacizumab
#13
Jian Chen, Fengcai DU, Baohong Hu, Cheng Chi, Hongjin Chu, Lixin Jiang, Peng Li, Zhaohua Gong
BACKGROUND/AIM: Bevacizumab combined with standard chemotherapeutics has become a choice of treatment for several kinds of cancers. Hypertension, third-degree albuminuria, thrombosis and cardiotoxicity are the reported side-effects of bevacizumab. Among them, cardiotoxicity is a most severe, but rare outcome. We report a case of a 62-year-old female with colorectal carcinoma who was given bevacizumab-containing chemotherapy for more than 20 months and achieved a stable disease during the entire course of treatment...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28738235/treatment-decisions-in-metastatic-colorectal-cancer-beyond-first-and-second-line-combination-therapies
#14
REVIEW
A Vogel, R D Hofheinz, S Kubicka, D Arnold
Median overall survival (OS) of patients with metastatic colorectal cancer (mCRC) has reached up to 30months in recent clinical trials of first line therapies. Following disease progression after the standard in both, 1st and 2nd line, combination chemotherapy with monoclonal antibodies, many patients maintain a good performance status and a significant proportion is motivated to undergo further therapy. Choices of treatment beyond the second line setting for mCRC are therefore becoming increasingly important...
May 4, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28729180/symptom-and-quality-of-life-improvement-in-lux-lung-8-an-open-label-phase-iii-study-of-second-line-afatinib-versus-erlotinib-in-patients-with-advanced-squamous-cell-carcinoma-of-the-lung-after-first-line-platinum-based-chemotherapy
#15
Enriqueta Felip, Vera Hirsh, Sanjay Popat, Manuel Cobo, Andrea Fülöp, Charles Dayen, José M Trigo, Richard Gregg, Cornelius F Waller, Jean-Charles Soria, Glenwood D Goss, James Gordon, Bushi Wang, Michael Palmer, Eva Ehrnrooth, Shirish M Gadgeel
INTRODUCTION: In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing during or after platinum-based chemotherapy. Patient-reported outcomes (PROs) and health-related quality of life (QoL) in these patients are presented. PATIENTS AND METHODS: Patients (n = 795) were randomized 1:1 to oral afatinib (40 mg/d) or erlotinib (150 mg/d)...
June 23, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28729151/standard-dose-pembrolizumab-in-combination-with-reduced-dose-ipilimumab-for-patients-with-advanced-melanoma-keynote-029-an-open-label-phase-1b-trial
#16
Georgina V Long, Victoria Atkinson, Jonathan S Cebon, Michael B Jameson, Bernie M Fitzharris, Catriona M McNeil, Andrew G Hill, Antoni Ribas, Michael B Atkins, John A Thompson, Wen-Jen Hwu, F Stephen Hodi, Alexander M Menzies, Alexander D Guminski, Richard Kefford, Benjamin Y Kong, Babak Tamjid, Archana Srivastava, Anna J Lomax, Mohammed Islam, Xinxin Shu, Scot Ebbinghaus, Nageatte Ibrahim, Matteo S Carlino
BACKGROUND: Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety and anti-tumour activity of standard-dose pembrolizumab in combination with reduced-dose ipilimumab. METHODS: In this open-label, phase 1b trial, we recruited patients from 12 medical centres in Australia, New Zealand, and the USA. Eligible patients were aged at least 18 years, had advanced melanoma, had an Eastern Coooperative Oncology Group performance status of 0 or 1, had measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1...
July 17, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28729021/ascend-8-a-randomized-phase-1-study-of-ceritinib-450-mg-or-600-mg-taken-with-a-low-fat-meal-versus-750-mg-in-fasted-state-in-patients-with-anaplastic-lymphoma-kinase-alk-rearranged-metastatic-non-small-cell-lung-cancer-nsclc
#17
Byoung Chul Cho, Dong-Wan Kim, Alessandra Bearz, Scott A Laurie, Mark McKeage, Gloria Borra, Keunchil Park, Sang-We Kim, Marwan Ghosn, Andrea Ardizzoni, Evaristo Maiello, Alastair Greystoke, Richard Yu, Karen Osborne, Wen Gu, Jeffrey W Scott, Vanessa Q Passos, Yvonne Y Lau, Anna Wrona
INTRODUCTION: Ceritinib 750 mg fasted is approved for treatment of anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) patients previously treated with crizotinib. Part 1 of ASCEND-8 study determined whether administering ceritinib 450 mg or 600 mg with a low-fat meal may enhance gastrointestinal (GI) tolerability vs 750 mg fasted in ALK+ NSCLC patients while maintaining similar exposure. METHODS: ASCEND-8 is a multicenter, randomized, open-label, phase 1 study...
July 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28723233/treatment-patterns-and-clinical-outcomes-with-pazopanib-in-patients-with-advanced-soft-tissue-sarcomas-in-a-compassionate-use-setting-results-of-the-spire-study
#18
Hans Gelderblom, Ian R Judson, Charlotte Benson, Ofer Merimsky, Giovanni Grignani, Daniela Katz, Klaus W Freivogel, Dara Stein, Minesh Jobanputra, Arron Mungul, Stephanie C Manson, Roberta Sanfilippo
BACKGROUND: A named patient program (NPP) was designed to provide patients with advanced soft-tissue sarcoma (aSTS) access to pazopanib, a multitargeted tyrosine kinase inhibitor. The SPIRE study was a retrospective chart review of participating patients. PATIENTS AND METHODS: Eligibility criteria for the NPP and SPIRE mirrored those of the pivotal phase-III study, PALETTE, which compared pazopanib with placebo in patients ≥18 years with aSTS and whose disease had progressed during or following prior chemotherapy or were otherwise unsuitable for chemotherapy...
July 19, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28715490/patterns-of-care-of-brain-tumor-related-epilepsy-a-cohort-study-done-in-italian-epilepsy-center
#19
Marta Maschio, Ettore Beghi, Marina M L Casazza, Gabriella Colicchio, Cinzia Costa, Paola Banfi, Stefano Quadri, Paolo Aloisi, Anna Teresa Giallonardo, Carla Buttinelli, Giada Pauletto, Salvatore Striano, Andrea Salmaggi, Riccardo Terenzi, Ornella Daniele, Giovanni Crichiutti, Francesco Paladin, Rosario Rossi, Giulia Prato, Federico Vigevano, Roberto De Simone, Federica Ricci, Marina Saladini, Fabrizio Monti, Susanna Casellato, Tiziano Zanoni, Diana Giannarelli, Giuliano Avanzini, Umberto Aguglia
Epilepsy is the most common comorbidity in patients with brain tumors. STUDY AIMS: To define characteristics of brain tumor-related epilepsy (BTRE) patients and identify patterns of care. Nationwide, multicenter retrospective cohort study. Medical records of BTRE patients seen from 1/1/2010 to 12/31/2011, followed for at least one month were examined. Information included age, sex, tumor type/treatments, epilepsy characteristics, antiepileptic drugs (AEDs). Time to modify first AED due to inefficacy and/or toxicity was assessed with the Kaplan-Meier method and Cox proportional hazard models were used to identify predictors of treatment outcome...
2017: PloS One
https://www.readbyqxmd.com/read/28711275/chemotherapy-induced-stroke-mimic-5-fluorouracil-encephalopathy-fulfilling-criteria-for-tissue-plasminogen-activator-therapy
#20
May Thuy Nguyen, Robyn Stoianovici, Luigi Brunetti
Stroke mimics, especially those involving chemotherapy related neurotoxicity, can confound the clinical diagnosis of acute stroke. Here we describe the case of a 63year-old male with a recent history of stage IIIC colon cancer who presented with confusion on the second day of modified FOLFOX6 (5-fluorouracil/oxaliplatin) chemotherapy and subsequently received alteplase, tissue plasminogen activator therapy (tPA), for presumed ischemic stroke. Magnetic resonance imaging scans after tPA administration did not reveal evidence of an infarction and the patients' neurological symptoms resolved completely after discontinuation of 5-fluorouracil (5-FU)...
July 6, 2017: American Journal of Emergency Medicine
keyword
keyword
31212
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"